EMEA-001664-PIP02-15-M05
Key facts
| Invented name |
Aimovig
|
| Active substance |
erenumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0475/2021
|
| PIP number |
EMEA-001664-PIP02-15-M05
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of migraine headaches
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|